



# Symposium

## *Development and Regulatory Aspects of Topical Dermatics Today*

January 27, 2010

BfArM, Kurt-G.-Kiesinger-Allee 3, D-53175 Bonn

Organizer:

GD Society for Dermopharmacy

in cooperation with

BfArM Federal Institute for Drugs and Medical Devices

Moderators:

H. C. Korting, München; U. Muazzam, Bonn;

M. Schäfer-Korting, Berlin



### Program

---

09:30 - 17:45

09:30 - 09:45

Opening ceremony

Word of welcome from GD  
(Society for Dermopharmacy)  
*J. Kresken, Viersen*

Word of welcome from BfArM  
(Federal Institute for Drugs and Medical  
Devices)  
*K. Broich, Bonn*

Introductory remarks  
*H. C. Korting, München*

09:45 - 10:25

Session 1: Dermatics - a world of its own

Chair: *M. Straube, Bonn,*  
*M. Schäfer-Korting, Berlin*

09:45 - 10:05

Which dermatics do we have?

*H. F. Merk, Aachen*

10:05 - 10:25

Which dermatics do we need?

*Th. Luger, Münster*

10:25 - 10:50

Get together/coffee break

10:50 - 12:30

Session 2: Identification and production of  
active pharmaceutical ingredients

Chair: *B. Kleuser, Potsdam,*  
*S. Laufer, Tübingen*

10:50 - 11:10

The regulatory framework for preclinical  
research

*T. Zapf, Bonn*

11:10 - 11:30

Target identification: general aspects and  
sphingosine-1-phosphate receptors as an  
example

*B. Kleuser, Potsdam*

11:30 - 11:50

Lead optimization: general aspects and MAP  
kinase inhibitors for psoriasis as an example

*S. Laufer, Tübingen*

11:50 - 12:10

Target identification and lead optimization:  
Fungal secreted aspartic proteinase  
inhibitors as a paradigm

*C. Borelli, München*



12:10 - 12:30

Production of active pharmaceutical ingredients: general aspects and sphingosine-1-phosphate and inhibitors of human polymerase alpha as examples  
*R. Zuhse, Luckenwalde*

12:30 - 13:30

Get together/lunch

13:30 - 14:10

Session 3: Characterization of active pharmaceutical ingredients

Chair: *Th. Luger, Münster,*  
*K.-P. Wilhelm, Schenefeld*

13:30 - 13:50

Toxicological characterization of new active pharmaceutical ingredients for dermatics  
*G. Hager, Tutzing*

13:50 - 14:10

Pharmacological characterization of new active pharmaceutical ingredients  
*T. Zollner, Berlin*

14:10 - 14:30

Get together/coffee break

14:30 - 15:30

Session 4: Aspects of formulation

Chair: *J. Fluhr, Berlin*  
*H. F. Merk, Aachen*

14:30 - 14:50

Regulatory aspects of pharmaceutical quality with dermatics  
*B. Tofern-Reblin, Bonn*

14.50 - 15.10

Optimizing conventional galenics: microemulsions as a paradigm  
*P. Schlupp, Gießen*

15:10 - 15:30

How to develop and characterize innovative formulations  
*M. Schäfer-Korting, Berlin*

15:30 - 16:00

Get together/coffee break

16:00 - 17:40

Session 5: Clinical development

Chair: *J. Regenold, Badenweiler,*  
*T. Zollner, Berlin*

16:00 - 16:20

Optimizing the development plan through scientific advice processes  
*J. Regenold, Badenweiler*

16:20 - 16:40

Human toxicology/phase I studies  
*J. Fluhr, Berlin*

16:40 - 17:00

Phase II trials  
*B. Hughes-Formella, Hamburg*

17:00 - 17:20

Phase III trials  
*K.-P. Wilhelm, Schenefeld*

17:20 - 17:40

Phase IV trials  
*E. Blümner, Frankfurt am Main*

17:40 - 17:45

Final remarks  
*U. Muazzam, Bonn*

